14 completed, 5 unknown, 3 terminated, 1 withdrawn. 13 Phase 2, 7 Phase 1, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 1 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Phase 3 | 4 | Completed 2, Unknown 2 |
| Not applicable | 1 | Completed 1 |
Follow Muromonab-CD3: new trials by email Literature Review of Muromonab-CD3 trials Research Report on Muromonab-CD3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM Foralumab, placebo, Omeprazole 20mg - NASH - Nonalcoholic Steatohepatitis, NAFLD | Phase 2 | Withdrawn | Tiziana Life Sciences LTD | 2017-12-01 | 2019-09-12 | |
| Oral OKT3 for the Treatment of Active Ulcerative Colitis Oral OKT3, Omeprazole - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 6 | 2011-04-07 | 2019-02-11 |
| Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome OKT3 - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Hadassah Medical Organization | 36 | 2010-09-01 | 2011-06-23 |
| Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 Otelixizumab, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Completed | GlaxoSmithKline | 179 | 2010-05-17 | 2017-09-15 |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies Clofarabine, Stem Cell Transplantation, Hematopoietic, OKT3 - Hematologic Malignancies | Phase 1 | Completed | St. Jude Children's Research Hospital | 34 | 2009-01-01 | 2017-01-02 |
| Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1 otelixizumab infusion plus physician determined standard of care, placebo infusion plus physician determined standard of care - Diabetes Mellitus, Type 1 | Phase 3 | Completed | GlaxoSmithKline | 272 | 2008-07-29 | 2017-10-03 |
| Oral OKT3 in Combination With Beta-D-Glucosylceramide OKT3, OKT3, GC, GC - Healthy | Phase 1 | Unknown | Hadassah Medical Organization | 20 | 2008-01-01 | 2009-02-04 |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies CliniMACS, Stem cell transplantation, Fludarabine - Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML) | Phase 2 | Completed | St. Jude Children's Research Hospital | 73 | 2007-12-14 | 2020-04-14 |
| ALL-SCT BFM International- HSCT in Children and Adolescents With ALL VP16, TBI, VP16, ATG - Lymphoblastic Leukemia, Acute, Childhood; | Phase 3 | Unknown | St. Anna Kinderkrebsforschung | 405 | 2007-01-01 | 2015-06-26 |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases muromonab-CD3, natural killer cell therapy, fludarabine phosphate - Graft Versus Host Disease, Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2006-12-01 | 2017-05-24 |
| Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer IL-2 (interleukin-2), OKT3, Cyclophosphamide - Kidney Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 3 | 2004-09-01 | 2012-10-26 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | St. Jude Children's Research Hospital | 40 | 2004-05-01 | 2017-06-19 |
| Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma IL-2, gp100:209-217, OKT3 - Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2004-03-01 | 2012-06-14 |
| Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia VP16, TBI, VP16, ATG - Lymphoblastic Leukemia, Acute, Childhood; | Phase 3 | Unknown | St. Anna Kinderkrebsforschung | 400 | 2003-07-01 | 2015-06-26 |
| Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis Muromonab-CD3, Cyclosporine - Myocarditis | Not applicable | Completed | Mayo Clinic | 40 | 2001-08-01 | 2015-03-25 |
| Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis Cyclosporine, methylprednisolone, Muromonab-CD3 - Myocarditis, Giant Cell Myocarditis | Phase 2 | Completed | Mayo Clinic | 40 | 1999-12-01 | 2010-09-09 |
| Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma aldesleukin, autologous tumor cell vaccine, muromonab-CD3 - Melanoma (Skin) | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 1997-06-01 | 2013-04-05 | |
| Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma aldesleukin, autologous tumor cell vaccine, muromonab-CD3 - Brain and Central Nervous System Tumors | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 60 | 1997-06-01 | 2013-04-05 |
| Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant anti-thymocyte globulin, filgrastim, muromonab-CD3 - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 1996-06-01 | 2012-12-11 | |
| Twins Study of Gene Therapy for HIV Infection Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro - Acquired Immunodeficiency Syndrome, HIV Infection | Phase 1 | Completed | National Human Genome Research Institute (NHGRI) | 48 | 1996-03-01 | 2008-02-08 |
Showing 20 of 23. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Myeloid, Acute (4) · Leukemia (3) · Myelodysplastic Syndromes (3) · Astrocytoma (2) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Central Nervous System Neoplasms (2) · Diabetes Mellitus, Type 1 (2) · Glioblastoma (2) · Gliosarcoma (2) · Graft vs Host Disease (2) · Hodgkin Disease (2) · Kidney Neoplasms (2) · Lymphoma (2)
National Cancer Institute (NCI) (3) · St. Jude Children's Research Hospital (3) · Barbara Ann Karmanos Cancer Institute (2) · GlaxoSmithKline (2) · Hadassah Medical Organization (2) · Mayo Clinic (2) · St. Anna Kinderkrebsforschung (2) · Brigham and Women's Hospital (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Human Genome Research Institute (NHGRI) (1) · St. Vincent Medical Center - Los Angeles (1) · Tiziana Life Sciences LTD (1) · University of Colorado, Denver (1)
United States (17) · Israel (3) · Italy (3) · Austria (2) · Denmark (2) · Germany (2) · Sweden (2) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Netherlands (1) · Poland (1) · Slovakia (1) · Spain (1)
Brandon Triplett, MD (3) · Adriana Balduzzi, MD (1) · Akif Yesilipek, MD Prof (1) · Andrew E. Sloan, MD (1) · Ann Woolfrey, MD (1) · Charles L. Wiseman, MD, FACP (1) · Christina Peters Peters, Prof MD PHD (1) · Ehud Zigmond, M.D. (1) · Jacek Toporski, MD (1) · Jacek Wachowiak, MD, Prof. (1) · James Yang, M.D. (1) · Jean-Hugues Dalle, Prof. MD (1) · Jerry Stein, Prof. MD (1)
PMID 15812540, PMID 21195303, PMID 25753432, PMID 33242441, PMID 16817692, PMID 19026310, PMID 25605857, PMID 26869631, PMID 31319153
P30CA022453 (2), P30CA015704 (1), R01AI053193 (1)